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Background: The proliferating activity of a single leukemia stem cell and the molecular mechanisms for their
quiescent property remain unknown, and also their prognostic value remains a matter of debate. Therefore, this
study aimed to demonstrate the quiescence property and molecular signature of leukemia stem cell and their
clinicopathological implications.
Methods: Single cell sorting and culture were performed in the various sets of hematopoietic stem cells including
CD34+CD38- acute myeloid leukemia (AML) cell population (ASCs) from a total of 60 patients with AML, and 11
healthy controls. Their quiescence related-molecular signatures and clinicopathological parameters were evaluated
in AML patients.
Results: Single cell plating efficiency of ASCs was significantly lower (8.6%) than those of normal hematopoietic
stem cells i.e.: cord blood, 79.0%; peripheral blood, 45.3%; and bone marrow stem cell, 31.1%. Members of the TGFβ
super-family signaling pathway were most significantly decreased; as well as members of the Wnt, Notch, pluripo-
tency maintenance and hedgehog pathways, compared with non ASC populations. mtDNA copy number of ASCs
was significantly lower than that of corresponding other cell populations. However, our data couldn’t support the prog-
nostic value of the ASCs in AML.
Conclusions: ASCs showed remarkable lower plating efficiency and slower dividing properties at the single cell level.
This quiescence is represented as a marked decrease in the mtDNA copy number and also linked with down-regulation
of genes in various molecular pathways.
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Acute myeloid leukemia (AML) is the most common
adult leukemia, characterized as a genetically and pheno-
typically heterogeneous disease [1]. Although AML is
generally regarded as a stem-cell disease, there is an on-
going debate on whether normal stem cells undergoing* Correspondence: mgshin@chonnam.ac.kr
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unless otherwise stated.leukemogenic mutations are the cause of leukemo-
genesis [2]. Since Lapidot et al. proposed the concept of
leukemia stem cells [3], many researchers demonstrated
that leukemic stem-like cells have crucial role in onco-
genesis, treatment and prognosis of AML [4-6]. In CD34+
AML, the CD34+ leukemic stem cells designated into
AML stem cells (ASCs) are characterized by the absence
of CD38 [3,4]. In spite of only a minority of cells within
AML, these ASCs are responsible for sustaining and
maintaining the leukemia [7]. It has been proven in vitro
that these stem cells are more resistant to chemotherapy,
compared to the progenitor CD34+CD38+ cells. In vivo,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cells are thought to differentiate, to a limited extent, pro-
ducing leukemic cells with an immunophenotype, usually
observed at diagnosis. Sensitive techniques allow early de-
tection of small numbers of these differentiated leukemic
cells, called minimal residual disease; these cells eventu-
ally causes relapse of the disease [4]. Therefore, it is im-
portant to understand how the biology of the leukemic
stem cell in AML differs from normal hematopoietic stem
cells.
Hematopoietic stem cells (HSCs) and leukemia stem
cells share many features and the extent to which they
differ will be the basis for the development of leukemia
stem cell-targeted therapies without considerable tox-
icity. The quiescence of stem cells was regarded to be of
critical biologic importance in protecting the stem cell
compartment [8]. Quiescence of stem cells might also be a
mechanism underlying resistance to cell cycle-dependent
cytotoxic therapy [9]. Some researchers examined the
gene expression profiles of CD34+CD38- cell popula-
tions, compared with CD34+CD38+ cell populations
using microarrays and found several different expres-
sions of genes, consistent with the relative quiescence of
stem cells [10]. However, the quiescence of ASCs has
scarcely been demonstrated at the level of single cell in
culture.
Mitochondria, the highly conserved organelles respon-
sible for cellular bioenergetic activity, might play a cru-
cial role in carcinogenesis [11]. Compared to the nuclear
genome, mitochondrial DNA (mtDNA) has a modified
genetic code, a paucity of introns, and the absence of
histone protection. The repair capacity of mtDNA is
limited, and the proximity of mtDNA to sites of reactive
oxygen species generation suggests that mitochondrial
DNA may be more susceptible to mutation than nuclear
DNA. Previous studies have shown that mtDNA muta-
tions might be implicated in pathogenesis and/or their
prognosis in various malignancies [12-14]. Although
stem cells possess lower intracellular mitochondrial
contents than other functional mature cells because
they generally reside in the G0 phase of the cell cycle
and require very little energy [15,16], it is not clear
about the mtDNA mutations in terms of the quiescence
of ASCs.
AML is maintained by a subpopulation of cancer initi-
ating cells that can regenerate themselves as well as give
rise to more differentiated and less proliferative cells that
constitute the bulk of the disease. However, there was
no comprehensive data regarding the direct confirmation
of quiescent characteristics of ASCs on the basis of single
cell experiments in vivo and in vitro. The aims of our
study were: (i) to demonstrate the quiescence of ASCs at
the single cell level, (ii) to elucidate the molecular signa-
ture of quiescent ASCs at the nuclear and mitochondriallevels, and (iii) to assign prognostic implications to ASCs
in patients with AML.
Methods
Study designs and specimens
A total of 60 patients with AML and 11 healthy controls
were enrolled after obtaining Chonnam National Univer-
sity Hwasun Hospital’s Institutional Review Board ap-
proval and informed consent. The patients who suffered
from AML M0 (n = 3), AML M1 (n = 5), AML M2 (n = 34),
AML M4 (n = 13), AML M5 (n = 3), and AML M6 (n = 2)
were 15 to 82 years aged with a median of 55.5 years.
Single cell sorting and culture were performed for the
evaluation of plating efficiency in the various sets of
hematopoietic stem cells. Plating efficiency of ASCs in
bone marrow (BM) obtained from 7 AML patients were
compared with that of single normal hematopoietic stem
cells, including BM (n = 6), peripheral blood (PB, n = 6)
and cord blood (CB, n = 5) which were obtained from
healthy controls (n = 11). The samples from the patients
and healthy controls were immediately frozen in liquid ni-
trogen on acquisition, for further molecular evaluation.
Their quiescence related-molecular signatures were evalu-
ated in terms of nuclear genomic changes and mtDNA
copy number. The clinicopathological parameters in AML
patients were also evaluated for prognostic implications of
ASCs.
Single cell sorting for CD34+CD38- cells and CD34+CD38+
cells
The proportion and frequency of ASC were examined
using a single cell sorter (BD FACS Aria, BD Biosciences,
USA). The samples were lysed by lysing buffer (BD Pharm
Lyse, Franklin Lakes, NJ, USA) and incubated at room
temperature for 15 minutes; they were then centrifuged
for 10 minutes at 1,200 rpm. Then, the cell pellets were
washed twice in phosphate-buffered saline (PBS). The
number of cells suspended in PBS was adjusted to 2 × 106
cells/mL. Next, 10 μL of anti-CD34 phycoerythrin (PE)–
conjugated antibodies (BD Bioscience, Franklin Lakes, NJ,
USA) and anti-CD38 fluorescein isothiocyanate (FITC)-
conjugated antibodies were added to each 12 × 75 mm
tube containing 100 μL of the cell suspension. After incu-
bation for 20 minutes at 4°C, the cells were washed using
cold PBS and resuspended in 0.5 mL of buffer. The cell
sorting was performed with a FACS aria (BD bioscience,
CO, USA) using 100 mW of the 488 nm line of an argon
laser (I-90, Coherent, Palo Alto, CA, USA) for excitation.
Forward scatter was the triggering parameter. Fluores-
cence of PE and FITC were detected using a 580/30 band
pass filter with gating based on forward scatter and PE
and FITC fluorescence, bulk cells of CD34+CD38-(ASC)
and CD34+CD38+ cells were collected in a 12 × 75 mm
tube containing 100 μL of PBS (Additional file 1).
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normal hematopoietic stem cells and ASCs
Single cell culture was performed according to a previ-
ous study [17]. Briefly, individual cells isolated from dif-
ferent sources were placed into each well of 96-well
microplates, ranging from 192 to 960 wells, as per the
number of cells obtained from each patient (Additional
file 2). Individual CD34 cells were cultured in serum-
free medium containing 100 ng/mL stem cell factor,
100 ng/mL Flt-3, 100 ng/mL thrombopoietin, and
50 ng/mL granulocyte colony-stimulating factor (G-CSF)
(all from Stem Cell Technologies, Vancouver, British
Columbia, Canada). After culture for 5 days, each well
of the microtiter plate was examined with an inverted
microscope (Olympus IX50, Melville, NY) to determine
growth and plating efficiency of the single CD34 cells.
The growth and proliferative capacities of normal
hematopoietic stem cells and ASCs were determined as
a function of plating efficiency (the number of the wells
in which more than two cells grew/total number of cells
in 96-well plate culture × 100). Growth was quantified
and graded with the following scoring system according
to cell number in each CD34 clone: grade 1, 5 or less
cells/well; grade 2, 6 to 10 cells/well; grade 3, 11 to 20
cells/well; grade 4, 21 or more cells/well.
PCR array and real time PCR for the genes contributing to
ASC quiescence
To screen for genes contributing to ASC quiescence, RNA
(1 μg) extracted from ASCs (CD34+CD38- cells) and non
ASCs (other CD34+ leukemic cell) isolated from BM sam-
ples obtained from a representative AML patient was con-
verted to cDNA and amplified using the RT2 First Strand
cDNA Synthesis Kit (SABiosciences, Frederick, MD,
USA). The quality of cDNA was confirmed with the
Human Stem Cell Signaling RT2 Profiler Array (SA-
Biosciences), which tests for RNA integrity, inhibitors of
reverse transcription and PCR amplification, and genomic
and general DNA contamination [18]. Gene expression
was then analyzed in these samples using the Human
Stem Cell Signaling RT2 Profiler PCR Array (SA-
Biosciences, PAHS-047), which profiles the expression of
84 genes involved in pluripotent cell maintenance and dif-
ferentiation. PCR products were quantified by measuring
SYBR Green fluorescent dye incorporation with ROX dye
reference. Functional gene groupings consisted of the
Hedgehog, Notch, TGF-b, and Wnt signaling pathways.
PCR amplification was conducted on an ABI Prism 7500
sequence detection system, and gene expression was cal-
culated using the comparative ΔΔCt-based fold-change
calculations from the uploaded raw threshold cycle data.
Subsequenctly, aberrantly expressed genes were further
confirmed by real time-PCR, using ASC and non-ASCs
isolated from BM samples obtained from 7 AML patients.Analysis of mtDNA copy number in ASCs and designated
AML cell populations
The mtDNA copy numbers were analyzed for the col-
lected bulk cells from the CD34+CD38- cells (ASCs),
CD34+CD38+ cells, CD33+ cells, and CD19+ cells.
Total DNA was then extracted with an AccuPrep Gen-
omic DNA Extraction Kit (Bioneer, Daejon, Korea). The
extracted DNA was resuspended in TE buffer (10 mM
Tris-HCl, 1 mM EDTA, pH 8.0) and photometrically
quantified. The lysate was briefly microcentrifuged and
stored at -20°C. A highly conserved region of the
mtDNA genome that codes for the CYTB gene [nucleo-
tide 14909 to nucleotide 15396; 488 base pairs (bp)] was
selected to quantify the number of mtDNA copies. The
PCR product of the CYTB gene was then subcloned into
the pCR®2.1-TOPO® vector, and transformed into com-
petent E. coli (TOP10 cells) using a TOPO TA cloning
kit (Invitrogen). Quantitative PCR was conducted with a
Rotor-Gene real-time centrifugal DNA amplification sys-
tem (Corbett Research), at a final reaction volume of
25 μL containing 12.5 μL of 2 × QuantiTect SYBR Green
PCR Master Mix (Qiagen), 0.4 μM each of the forward
and reverse primers for the CYTB gene, 5 μL of tem-
plate DNA (20 ng/reaction) or standard and RNase-free
water. The mtDNA copy number of this calibrator was
determined by dividing the total DNA concentration by
the weight of each plasmid molecule. The length of the
pCR®2.1-TOPO® vector was 3931 bp; thus, the cloned
vector was a total of 4419 bp in length. After spectro-
photometric determination of the plasmid DNA concen-
tration (X), the copy number (Y) of the standard CYTB
gene molecules was calculated using the following for-
mula: X μg/μL plasmid DNA/4419 (plasmid length) ×
660 × 6.022 × 1023 = Y molecules/μL. The molecular con-
centration of the plasmid stock solutions was diluted
from 5.8 × 108 copies to 5.8 × 105 copies/μL, in order to
generate the calibration curves. Thermal cycling condi-
tions were as follows: one cycle of 50°C for 2 minutes
and 95°C for 15 minutes, followed by 35 cycles of 94°C
for 20 seconds, 56°C for 30 seconds, and 72°C for
30 seconds.
The clinicopathological implications of the ASCs in AML
patients
The clinicopathological parameters were evaluated as
follows: age, sex, FAB classification, hemoglobin (Hgb),
white blood cell count (WBC), platelet count (PLT), BM
blast%, cytogenetic groups, the number of expired cases,
the number of relapse cases, overall survival (OS)
months, and relapse free survival (RFS) months. These
parameters were analyzed by two groups according to
the ASCs ratio (ASCs per total CD34+ cells) groups;
group of low ASC ratio less than 0.1 (n = 27) and group
of high ASCs ratio more than 0.1 (n = 33).
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Values of the average plating efficiency (%) of ASCs and
variable normal HSCs were compared using the Mann-
Whitney test for 2 groups and the Kruskal-Wallis test
with Dunn’s multiple comparison correction was used for
comparisons between 3 or more groups. The chi-square
test was used to determine statistical differences in the pa-
rameters of two groups according to the ASCs ratio (ASCs
per total CD34+ cells). OS time was defined as the time
between diagnosis and death from any cause. RFS was de-
fined as the time between diagnosis and relapse or disease
progression from underlying disease. RFS and OS were es-
timated by the Kaplan-Meier estimate.
Results
Remarkable lower plating efficiency of ASCs than normal
HSCs by single cell culture system
Figure 1 represented the morphology of the single-cell-
derived clones originated from HSCs and ASCs. The
proliferative properties of individual normal single hema-
topoietic stem cells varied according to the source of sam-
ples (Figure 1 and Figure 2B). When we subclassified the
grade of plating efficiency, normal HSCs obtained fromFigure 1 Morphology of single hematopoietic and AML stem cell clon
placed in separate wells within 96-well plates and cultured in serum-free med
colony-stimulating factor. After 5 days of culture, each well was examined usi
the single stem cell. (A) Normal HSCs obtained from adult bone marrow show
Almost all of HSCs obtained from cord blood showed high proliferative prope
remarkable low level at Grade 1. Detailed methods and analysis of plating eadult BM showed variable degrees of proliferative poten-
tials with grade 1 to grade 4, however, almost all of HSCs
obtained from CB had high proliferative properties with
grade 4. Notably, ASCs showed remarkably low prolifera-
tive potentials (Figure 1 and Figure 2B). When we com-
pared the plating efficiency of single HSCs and ASCs, CB
showed the highest average plating efficiency at 79.0%
(range, 71.9% to 87.5%; median, 82.9%). PB showed the
second-highest plating efficiency at 45.3% (range, 32.3%
to 58.3%; median, 44.5%) and BM stem cells followed
third, at 31.1% (range, 7.3% to 39.1%; median, 36.1%). Of
note, single ASC from AML patients showed a sig-
nificantly lower plating efficiency, 8.6% (range, 3.6% to
16.7%; median, 10.9%) than did normal HSCs (CB, p =
0.0025; PB, p = 0.0012; and BM, p = 0.0221) (Figure 2A).
These results directly confirmed the quiescent and slowly
dividing properties of ASCs. In addition, the plating effi-
ciency of normal HSCs varied by origin in the healthy
donors.
Identification of genes contributing to ASC quiescence
Of the 84 genes examined by human stem cell signaling
profiler array, we found that the expression of 27 geneses. Single cells, either hematopoietic stem cells (HSCs) or ASCs, were
ium containing stem cell factor, Flt-3, thrombopoietin, and granulocyte
ng an inverted microscope to determine growth and plating efficiency of
ed variable degree of proliferative potentials from Grade 1 to 4. (B)
rties at Grade 4. (C) The plating efficiency of single ASCs remained at a
fficiency of each single cell are described in the Methods section.
Figure 2 Comparison of plating efficiency and proliferation capacities in single normal HSCs and ASCs. The growth and proliferation
capacities of single HSCs and ASCs were quantified and graded with the following scoring system according to the number of cells in each
well of 96 microplate: Grade 1, ≤5 cells/well; Grade 2, 6 to 10 cells/well; Grade 3, 11 to 20 cells/well; and Grade 4, ≥21 cells/well. (A) The plating
efficiency of single ASC was significantly lower than that of normal HSCs obtained from cord blood (CB), peripheral blood (PB), and adult bone
marrow (BM). The plating efficiency of single HSCs varied among source samples. Values for plating efficiency of ASCs isolated from BM
obtained from 7 AML patients are indicated with black circles; while those of normal HSCs in BM and PB obtained from healthy controls (n = 6)
are indicated with white circles; and those for CB obtained from healthy controls (n = 5) are indicated with gray circles. (B) Almost all single CB
cells showed high proliferative capacity of Grade 4; BM and PB stem cells showed similar grades of single cell plating efficiency. However,
almost all single ASCs showed significantly lower dividing property at Grade 1. Statistical significance is indicated as follows: *, p-value < 0.05
and **, p-value < 0.01.
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compared with that observed in non-ASCs (Additional
file 3). Members of the TGFβ super-family signaling path-
way (ACVR1C, ACVR2B, BMPR1A, BMPR2, CREBBP,
E2F5, LTBP1, LTBP4, RBL2, SMAD2, SMAD3, SMAD9
and TGFBR1) were most commonly significantly de-
creased; as well as members of the Wnt (FZD3, FZD5,
LRP6, NFATC4 and BCL9L); FGF (FGFR1, FGFR2,
FGFR3); Notch (Notch 3, Notch 4 and RBPJL); pluripo-
tency maintenance (IL6ST and LIFR); and hedgehog
(GLI1) pathways. Among them, the expression of the eight
genes i.e. fibroblast growth factor receptor 1 (FGFR1), GLI
family zinc finger 1 (GLI1), bone morphogenetic protein
receptor, type IA (BMPR1A), interleukin 6 signal trans-
ducer (IL6ST), frizzled family receptor 5 (FZD5), Notch 3,
CREB binding protein (CREBP), and retinoblastoma-like 2
(RBL2) had >10-fold decrease compared with that ob-
served in counterpart non-ASCs (Table 1 and Figure 3).Lower mtDNA copy number of ASCs than those of
matched general leukemic cell populations
There were no significant statistical differences between
the ASCs (CD34+CD38-) and the CD19+ normal con-
trol cells (p = 0.4785). However, the mtDNA copy num-
ber of each sorted AML cell populations (CD33+ cells
and CD38+ cells) were higher than ASCs (p = 0.0081
and p = 0.048). ASCs had a lower mtDNA copy number
than non-ASCs (CD34+CD38+ cells), without statisti-
cally significant difference (p = 0.0769) (Figure 4).Clinical and laboratory implications of ASCs
Patient demographics according to ASC ratio to total
CD34+ cells were summarized in Table 2. There were
no significant differences in sex, age, WBC, PLT, Hgb,
BM blast%, and the number of expired or relapse cases.
There were no significant differences also between
groups according to FAB classifications, FLT3 mutation
status, cytogenetic groups, and CD34%. However, the
group of ASCs ratio more than 0.1 showed shorter OS
than the group with ASCs ratio less than 0.1, but no
statistical significance was noticed (median, 7 months vs
12 months; p = 0.211). When we analyzed OS according
to the ASCs ratio and cytogenetic groups, the group of
ASCs ratio with more than 0.1 showed similar prognosis
with the unfavorable cytogenetic groups. The group of
ASC ratio with less than 0.1, on the other hand, showed
good prognosis similar to the favorable cytogenetic
group (Figure 5). However, there were no statistically
significant differences in RFS according to AML patient’s
group with different ASCs ratio and proportion of total
leukemic cells.Discussion
This study presented evidence that ASCs obtained from
the patients with AML showed significantly lower plat-
ing efficiency at the level of the single cell; this finding
directly confirmed quiescent and slowly dividing proper-
ties of the ASCs by the single cell biological approach. We
investigated the status of ASC mitochondria because, in
Table 1 Relative down-regulation of genes involved in proliferative activity in ASCs, as determined by PCR array and
real-time PCR
Genes involved in proliferative activity
BMPR1A CREBBP RBL2 FZD5 FGFR1 Notch 3 IL6ST GLI1
Fold-changes in gene expression (ASCs/non-ASCs)* -12.8075 -11.6383 -11.3575 -12.5726 -14.0221 -12.309 -12.6345 -12.9973
Relative mRNA expression†
ASC 1 106.2 109.8 110.3 109.5 107.5 111.7 111.0 112.8
ASC 2 101.4 106.9 111.2 111.9 104.7 107.0 106.1 109.1
ASC 3 117.5 121.4 120.7 121.8 119.6 123.5 120.2 123.1
ASC 4 98.9 103.9 102.8 106.6 101.9 104.0 103.3 107.2
ASC 5 102.4 101.5 105.3 103.1 100.8 105.1 102.4 104.3
ASC 6 125.7 128.9 110.9 131.7 125.7 124.7 124.5 128.9
ASC 7 104.1 107.6 110.4 111.4 108.9 112.1 108.3 107.7
Non ASC 1 125.8 125.1 128.7 128.3 125.2 129.6 128.4 131.5
Non ASC 2 93.4 96.7 99.2 100.4 96.6 98.9 98.1 96.9
Non ASC 3 125.6 134.2 127.9 132.0 130.4 131.6 128.2 133.0
Non ASC 4 132.7 139.0 135.6 138.7 135.4 140.4 130.5 141.2
Non ASC 5 106.0 111.4 108.7 112.6 109.2 110.8 115.0 113.8
Non ASC 6 123.3 131.3 143.5 129.2 127.7 130.8 129.0 131.8
Non ASC 7 122.1 127.5 126.6 129.1 124.1 121.9 126.2 129.4
Average relative mRNA expression of ASCs 108.0 111.4 110.2 113.7 109.8 112.6 110.8 113.3
Average relative mRNA expression of non ASCs 113.8 118.1 117.8 119.7 116.2 118.5 116.9 119.8
Abbreviations: BMPR1A Bone morphogenetic protein receptor, type IA, CREBBP CREB binding protein, RBL2 Retinoblastoma-like 2, FZD5 Frizzled family receptor 5,
FGFR1 Fibroblast growth factor receptor 1, IL6ST Interleukin 6 signal transducer, GLI1 GLI family zinc finger 1.
*Fold-changes of down-regulated gene expression in ASCs relative to non-ASCs obtained from a representative AML patient.
†Relative mRNA expression was calculated as follows: 100 × threshold cycles of target/β-actin.
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lar organelle is known to play an essential role as the main
powerhouse in ATP generation and is implicated as the
internal initiating center during apoptosis. Therefore, this
study studied the change of mitochondrial genome in vari-
ous cellular populations including CD34+CD38- cell
population as well as CD34+CD38+ AML cells. ASCs had
a significant reduction in mtDNA copy number, which
may lead to decreased mitochondrial biogenesis and de-
rangement of enzyme complex activities within the mito-
chondrial respiratory chain for ATP synthesis. These
findings prompted us to investigate molecular alterations
of ASCs compared with counterpart AML cells. The study
using PCR arrays for genes involved in participating stem
cell signaling pathways revealed remarkable down regula-
tion of gene expressions in the important genes for main-
taining stem cell stemness, self-renewal and proliferation.
These molecular signatures which were revealed in single
cell culture linked appropriately to unique properties of
ASC cell biology and therapeutic targets of AML.
We assayed that individual normal single hematopoietic
stem cells had variable proliferative capabilities and, above
all, ASCs were the most dormant cells. This variation
might be due to cellular environment-regulated stem cellquiescence, e.g. a bone marrow niche, as well as intrinsic
molecular regulation of mandatory genes. The molecular
crosstalk between HSCs and the cellular components of
their niches was thought to control the balance between
HSC self-renewal and differentiation [19]. Several recently
identified genes that perturb HSC quiescence also disrupt
stem cell maintenance and homeostatic blood cell produc-
tion. It was suggested that the proliferative activity of HSC
is normally restricted by both HSC intrinsic factors and
extrinsic factors produced in the HSC niche [20]. ASCs
had major clinical relevance due to their unique proper-
ties, such as slow mitosis, increased multidrug resistance
and lower expression of Fas/Fas-L and Fas-induced apop-
tosis. ASCs are often resistant to both conventional
chemotherapy and targeted therapies, are retained viable
and contribute to relapse following discontinuation of
therapy [21]. There has been increased interest recently to
develop approaches based either on activating quiescent
cancer stem cell to induce their cell cycle entry and in-
crease their sensitivity to other treatments, or identifying
agents that are capable of directly targeting quiescent can-
cer stem cells [21,22].
Although stem cells have the potential for self-renewal,
they spend the majority of their time in the G0 phase of
Figure 3 Confirmation of genes showing significant down-regulated expression in ASCs. Scatter plots revealed the expression status of
genes showing down-regulation in ASCs and non-ASC leukemic cells. Initial screening for alterations in gene expression was performed using
human stem cell signaling PCR array of samples from a representative AML patient and the results were further confirmed by quantitative real
time PCR analysis of individual candidate genes by using samples obtained from 7 AML patients.
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been demonstrated in aspects of molecular signaling
pathway, associated with cell cycle regulation. This study
also found markedly declined expressions of the eight
genes related to cell proliferation and differentiation.
FGF signaling pathway was known to lead the loss of qui-
escence and depletion of the resident stem cell popula-
tions, which eventually diminishes regenerative capacity
[24]. In Hedgehog signaling pathway, Merchant et al. re-
vealed that the loss of the downstream effector Gli1 lead
to reduced proliferation [25]. Notch is a crucial signaling
pathway involved in the generation of cell diversity and
stem-cell maintenance in different systems [26]. TGF-β
signaling controls numerous cellular processes including
cell proliferation, differentiation and apoptosis, both dur-
ing embryogenesis and adulthood. The role of TGF-β in
stem cell quiescence had been suggested not only in
hematopoietic stem cells [27,28], but also in neural stemcells [29], and neonatal germ cell [30] with compelling
supportive evidence. Evidence for a role of Wnt proteins
in hematopoiesis arose from experiments demonstrating
that multiple Wnts could expand hematopoietic stem/
progenitor cells in culture [31]. A number of other genes
and signaling pathways have been implicated in regulat-
ing stem cell quiescence as well [19].
Mitochondria play an essential role in ATP generation
for cells and tissues, and is an internal center of apop-
tosis as well. Moreover, alteration of mitochondria and
mtDNA sequence are now regarded as important causa-
tive factors for carcinogenesis, as well as metastasis.
Therefore, we examined the mitochondrial genome in
ASC and non-ASC populations. Primary AML cells, as
non-ASC populations, had a significantly increased mtDNA
copy number compared to ASC populations. In general,
mitochondria has the major role in cell proliferation and
differentiation with high requirement of ATP, causing
Table 2 Demographics and clinical characteristics of AML









Male/Female 14/13 14/19 0.466
Age, years Min 15 16 0.471
Max 81 82




M0 2 (7.4) 1 (3.0)
M1 3 (11.1) 2 (6.1)
M2 15 (55.6) 19 (57.6)
M4 6 (22.2) 7 (21.2)
M5 1 (3.7) 2 (6.1)




Favorable 9 (33.3) 9 (27.3)
Intermediate 16 (59.3) 19 (57.6)




%CD34+ <5 2 (7.4) 7 (21.2)
5≤%CD34+ <20 3 (11.1) 10 (30.3)
20 ≤%CD34+ 22 (81.5) 16 (48.5)
WBC (*1000/uL) Median 30.1 25.2 0.379
PLT (*1000/uL) Median 37 44 0.698
Hemoglobin (g/dL) Median 8.5 8.2 0.871
BM blast, % Median 73 60 0.078
Expired case, N (%) 9 (33.3) 16 (48.5) 0.236
Relapse case,
N (%)







ASCs ratio, the number of AML stem cell per the number of CD34+ cells;
N, number; PLT, platelet; BM, bone marrow.
*Cytogenetic groups were divided according to the NCCN guideline [44].
Figure 4 The change of mtDNA copy number in each cell
population from total bone marrow cells of AML. Significant
reduction of mtDNA copy number was observed in ASCs and CD19+
cell populations compared with other cells. There was statistical
differences in mtDNA copy numbers from AML cells (CD33+ cells and
CD38+ cells) and ASCs (CD34+CD38- cell) (p < 0.05), but the mtDNA
copy number of ASCs was similar to those of normal control cells
(CD19+). ASCs showed a lower mtDNA copy number than did
non-ASCs (CD34+CD38+ cells), which was not statistically significant
(p = 0.0769). Statistical significances were indicated as follows: *, p-value
<0.05; and **, p-value <0.01.
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creased mtDNA copy number of non ASCs reflected ac-
tive proliferation of leukemic cells. Excess mtDNA
replications and increased mtDNA copy number are
regarded as an initial event of pathological mitochondrial
genome alteration; they may occur as a compensatory
mechanism for mtDNA aberrations and mitochondrial
dysfunction. Loss of mtDNA copy number in ASCs popu-
lations was likely due to either nuclear or mtDNA muta-
tions [32]. Mitochondrial aberrations, including mtDNA
somatic mutations and copy number variations, have been
frequently reported in various human cancers [33-38].
However, the contents of mtDNA copy number could be
influenced by various cancers in different manners. Lee
et al. summarized that there is a significant reduction of
mtDNA copy number in 57.4% (31/54) of the hepatocellu-
lar carcinoma, 54.8% (17/31) of the gastric cancers, 22.6%
(7/31) of the lung cancers, and 28.0% (7/25) of the colo-
rectal cancers compared with the corresponding non-
tumorous tissues [39]. On the other hand, in breast cancer
and colorectal cancer, increased mtDNA copy number
was related to cancer risk [40,41]. Notably, variable
mtDNA content had been reported as a prognostic factor
for gastric cancer, colorectal cancer and non-small cell
lung cancer [33,41,42]. These studies suggested that
mtDNA copy number was closely related to not only
tumorigenesis, but also regeneration of cancer cells as
well.
Notably, the current study showed that the group with
higher ASCs ratio (>0.1) had an unfavorable prognosis, al-
beit without statistical significance. This study, however,could not demonstrate any direct evidence of AML prog-
nostic value with the ratio of ASCs. Several studies dem-
onstrated that the quiescent, non-cycling state of ASCs
may contribute to poor prognosis [4-6,9]. Conventional
chemotherapeutic drugs that target leukemic cells have
been shown to be ineffective in completely eradicating
ASCs. The quiescent nature of ASCs might explain the
low rates of long-term remission and multidrug resistance
Figure 5 Clinical implication of the proportion of ASCs. (A, C) Compared to an ASC ratio of <0.1, an ASC ratio of >0.1 in the AML patients
group resulted in a shorter overall survival, similar to that observed in cytogenetic risk groups, albeit without statistical significance (p = 0.211).
(B, D) There was no statistically significant difference in relapse-free survival with respect to ASC ratio.
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a matter of debate. Gerber et al. found that ASCs popula-
tion could be divided according to the aldehyde dehydro-
genase activity and CD34+CD38- fraction with high levels
of aldehyde dehydrogenase activity was a potential marker
for clinically significant minimal residual disease in AML
[19]. Similar to our study, they also were not able to show
the frequency of the ASCs as a surrogate prognostic
marker in AML [19]. This might be caused by that ASCs
population is heterogeneous, although CD34+CD38- cells
are enriched for ASC. Further evaluation would be neces-
sary to define this heterogeneity and clinical impact of
ASCs.
Conclusions
In conclusion, this study demonstrated the quiescence of
ASCs with lower plating efficiency and slower dividing
properties at the single cell level. This quiescence is rep-
resented as a marked decrease in the mtDNA copy num-
ber and also linked with down-regulation of genes in
various molecular pathways. These findings might be
used to improve the understanding of the molecular
pathophysiology of AML as well as guide to novel treat-
ment targeting ASCs.
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efficiency in the various sets of hematopoietic stem cells. Briefly,individual CD34 cells placed into separate wells of 96-well plates were
cultured in serum-free medium containing 100 ng/mL stem cell factor,
100 ng/mL Flt-3, 100 ng/mL thrombopoietin, and 50 ng/mL granulocyte
colony-stimulating factor (G-CSF) (all from Stem Cell Technologies,
Vancouver, British Columbia, Canada). After culture for 5 days, each well
of the microtiter plate was examined with an inverted microscope
(Olympus IX50, Melville, NY) to determine growth and plating efficiency
of the single CD34 cells. Their molecular signatures related with
quiescence were evaluated in terms of nuclear genomic changes and
mtDNA copy number. The clinicopathological parameters in AML patients
were also evaluated for the prognostic implication of ASC.
Additional file 2: Plating efficiency (%) of different hematopoietic
stem cell sources and AML stem cells.
Additional file 3: Human stem cell-signaling PCR array profiles for
fold-down regulation genes in ASCs compared to non-ASCs
obtained from a representative AML patient.Abbreviations
AML: Acute myeloid leukemia; ASCs: AML stem cells; HSCs: Hematopoietic
stem cells; mtDNA: Mitochondrial DNA; BM: Bone marrow; PB: Peripheral
blood; CB: Cord blood; PBS: Phosphate-buffered saline; PE: Phycoerythrin;
FITC: Fluorescein isothiocyanate; G-CSF: Granulocyte colony-stimulating
factor; Hgb: Hemoglobin; WBC: White blood cell count; PLT: Platelet count;
OS: Overall survival; RFS: Relapse free survival.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
MGS was the principal investigator and takes primary responsibility for the
paper; EJW performed research, analyzed data and wrote the paper; HRK
performed experiments, research, and analyzed data; RYP performed
experiments; SYC, JHS, SPS, DWR and MS supervised and advised
experimental procedures and data; MGS designed research, analyzed data
and co-wrote the paper. All authors read and approved the final manuscript.
Won et al. BMC Cancer  (2015) 15:217 Page 10 of 11Acknowledgements
This study was supported by the National Research Foundation of Korea
(NRF) and grants (No. 2011-0015304), the NRF Basic Science Research
Program (grant 2010-0024326), the Leading Foreign Research Institute
Recruitment Program (No. 2011-0030034) through the NRF funded by the
Ministry of Education, Science and Technology (MEST), and a grant from the
National R&D Program for Cancer Control, Ministry of Health & Welfare,
Republic of Korea (No. 2013-1320070).
Author details
1Department of Laboratory Medicine, Chonnam National University Medical
School and Chonnam National University Hwasun Hospital, Hwasun, South
Korea. 2Brain Korea 21 Project, Center for Biomedical Human Resources,
Chonnam National University, Gwangju, South Korea. 3Environment Health
Center for Childhood Leukemia and Cancer, Chonnam National University
Hwasun Hospital, Hwasun, South Korea. 4Department of Cell Therapy, Fraunhofer
Institute for Cell Therapy and Immunology, Leipzig, Germany. 5College of Korean
Medicine, Dongshin University, Naju, South Korea.
Received: 18 November 2014 Accepted: 20 March 2015
References
1. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease
variety. Hematology Am Soc Hematol Educ Program. 2008;2008:1–11.
2. van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B.
The novel AML stem cell associated antigen CLL-1 aids in discrimination
between normal and leukemic stem cells. Blood. 2007;110:2659–66.
3. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al.
A cell initiating human acute myeloid leukaemia after transplantation into
SCID mice. Nature. 1994;367:645–8.
4. van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S,
et al. High stem cell frequency in acute myeloid leukemia at diagnosis
predicts high minimal residual disease and poor survival. Clin Cancer Res.
2005;11:6520–7.
5. Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, Gastaut JA, et al.
Human acute myeloid leukemia CD34+/CD38- progenitor cells have
decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced
immunogenicity, and impaired dendritic cell transformation capacities.
Cancer Res. 2000;60:4403–11.
6. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al.
Chemotherapy-resistant human AML stem cells home to and engraft within
the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315–21.
7. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat Med.
1997;3:730–7.
8. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, et al.
Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science.
2000;287:1804–8.
9. Dunn DM, Culhane SE, Taussig HN. Children's appraisals of their experiences
in out-of-home care. Child Youth Serv Rev. 2010;32:1324–30.
10. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A,
et al. Gene expression profiles of AML derived stem cells; similarity to
hematopoietic stem cells. Leukemia. 2006;20:2147–54.
11. Hatzi VI, Terzoudi GI, Pantelias GE, Makropoulos V. Mitochondria
malfunctions as mediators of stem-cells' related carcinogenesis: a hypothesis
that supports the highly conserved profile of carcinogenesis. Med Hypotheses.
2013;80:70–4.
12. Lim SW, Kim HR, Kim HY, Huh JW, Kim YJ, Shin JH, et al. High-frequency
minisatellite instability of the mitochondrial genome in colorectal cancer
tissue associated with clinicopathological values. Int J Cancer.
2012;131:1332–41.
13. Kim HR, Shin MG, Kim MJ, Kim HJ, Shin JH, Suh SP, et al. Mitochondrial DNA
aberrations of bone marrow cells from patients with aplastic anemia.
J Korean Med Sci. 2008;23:1062–7.
14. Lee S, Shin MG, Jo WH, Kim MJ, Kim HR, Lee WS, et al. Association between
Helicobacter pylori-related peptic ulcer tissue and somatic mitochondrial
DNA mutations. Clin Chem. 2007;53:1390–2.
15. Facucho-Oliveira JM, Alderson J, Spikings EC, Egginton S, St John JC.
Mitochondrial DNA replication during differentiation of murine embryonic
stem cells. J Cell Sci. 2007;120:4025–34.16. Inoue S, Noda S, Kashima K, Nakada K, Hayashi J, Miyoshi H. Mitochondrial
respiration defects modulate differentiation but not proliferation of
hematopoietic stem and progenitor cells. FEBS lett. 2010;584:3402–9.
17. Shin MG, Kajigaya S, Tarnowka M, McCoy Jr JP, Levin BC, Young NS.
Mitochondrial DNA sequence heterogeneity in circulating normal human
CD34 cells and granulocytes. Blood. 2004;103:4466–77.
18. Shin MG, Kajigaya S, McCoy Jr JP, Levin BC, Young NS. Marked
mitochondrial DNA sequence heterogeneity in single CD34+ cell clones
from normal adult bone marrow. Blood. 2004;103:553–61.
19. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, et al. A
clinically relevant population of leukemic CD34(+)CD38(-) cells in acute
myeloid leukemia. Blood. 2012;119:3571–7.
20. Forsberg EC, Passegue E, Prohaska SS, Wagers AJ, Koeva M, Stuart JM, et al.
Molecular signatures of quiescent, mobilized and leukemia-initiating
hematopoietic stem cells. PLoS One. 2010;5:e8785.
21. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793–807.
22. Slavin S, Moss RW, Bakacs T. Control of minimal residual cancer by low dose
ipilimumab activating autologous anti-tumor immunity. Pharmacol Res.
2014;79:9–12.
23. Gothot A, Pyatt R, McMahel J, Rice S, Srour EF. Functional heterogeneity of
human CD34(+) cells isolated in subcompartments of the G0/G1 phase of
the cell cycle. Blood. 1997;90:4384–93.
24. Chakkalakal JV, Jones KM, Basson MA, Brack AS. The aged niche disrupts
muscle stem cell quiescence. Nature. 2012;490:355–60.
25. Merchant A, Joseph G, Wang Q, Brennan S, Matsui W. Gli1 regulates the
proliferation and differentiation of HSCs and myeloid progenitors. Blood.
2010;115:2391–6.
26. Bigas A, D'Altri T, Espinosa L. The Notch pathway in hematopoietic stem
cells. Curr Top Microbiol Immunol. 2012;360:1–18.
27. Larsson J, Blank U, Helgadottir H, Bjornsson JM, Ehinger M, Goumans MJ,
et al. TGF-beta signaling-deficient hematopoietic stem cells have normal
self-renewal and regenerative ability in vivo despite increased proliferative
capacity in vitro. Blood. 2003;102:3129–35.
28. Batard P, Monier MN, Fortunel N, Ducos K, Sansilvestri-Morel P, Phan T, et al.
TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative
control of cell cycle and induces CD34 antigen up-modulation. J Cell Sci.
2000;113:383–90.
29. Falk S, Wurdak H, Ittner LM, Ille F, Sumara G, Schmid MT, et al. Brain area-
specific effect of TGF-beta signaling on Wnt-dependent neural stem cell
expansion. Cell Stem Cell. 2008;2:472–83.
30. Moreno SG, Attali M, Allemand I, Messiaen S, Fouchet P, Coffigny H, et al.
TGFbeta signaling in male germ cells regulates gonocyte quiescence and
fertility in mice. Dev Biol. 2010;342:74–84.
31. Van Den Berg DJ, Sharma AK, Bruno E, Hoffman R. Role of members of the
Wnt gene family in human hematopoiesis. Blood. 1998;92:3189–202.
32. Moraes CT. What regulates mitochondrial DNA copy number in animal
cells? Trends Genet. 2001;17:199–205.
33. Zhang G, Qu Y, Dang S, Yang Q, Shi B, Hou P. Variable copy number of
mitochondrial DNA (mtDNA) predicts worse prognosis in advanced gastric
cancer patients. Diagn Pathol. 2013;8:173.
34. Wallace DC. A mitochondrial paradigm of metabolic and degenerative
diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev
Genet. 2005;39:359–407.
35. Zheng S, Qian P, Li F, Qian G, Wang C, Wu G, et al. Association of
mitochondrial DNA variations with lung cancer risk in a Han Chinese
population from southwestern China. PLoS One. 2012;7:e31322.
36. Masuda S, Kadowaki T, Kumaki N, Tang X, Tokuda Y, Yoshimura S, et al.
Analysis of gene alterations of mitochondrial DNA D-loop regions to
determine breast cancer clonality. Br J Cancer. 2012;107:2016–23.
37. Xu E, Sun W, Gu J, Chow WH, Ajani JA, Wu X. Association of mitochondrial
DNA copy number in peripheral blood leukocytes with risk of esophageal
adenocarcinoma. Carcinogenesis. 2013;34:2521–4.
38. Warowicka A, Kwasniewska A, Gozdzicka-Jozefiak A. Alterations in mtDNA: a
qualitative and quantitative study associated with cervical cancer development.
Gynecol Oncol. 2013;129:193–8.
39. Lee HC, Yin PH, Lin JC, Wu CC, Chen CY, Wu CW, et al. Mitochondrial
genome instability and mtDNA depletion in human cancers. Ann N Y Acad
Sci. 2005;1042:109–22.
40. Thyagarajan B, Wang R, Nelson H, Barcelo H, Koh WP, Yuan JM.
Mitochondrial DNA copy number is associated with breast cancer risk. PLoS
One. 2013;8:e65968.
Won et al. BMC Cancer  (2015) 15:217 Page 11 of 1141. Feng S, Xiong L, Ji Z, Cheng W, Yang H. Correlation between increased
copy number of mitochondrial DNA and clinicopathological stage in
colorectal cancer. Oncol Lett. 2011;2:899–903.
42. Xu H, He W, Jiang HG, Zhao H, Peng XH, Wei YH, et al. Prognostic value of
mitochondrial DNA content and G10398A polymorphism in non-small cell
lung cancer. Oncol Rep. 2013;30:3006–12.
43. Shin MG, Kajigaya S, Levin BC, Young NS. Mitochondrial DNA mutations in
patients with myelodysplastic syndromes. Blood. 2003;101:3118–25.
44. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines
in Oncology. Acute Myeloid Leukemia, Version 2.2012. Available at
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
Accessed June 11, 2012.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
